Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes

Journal of Clinical Investigation

Volumn 113, Issue 10, 2004, Pages 1473-1481

  Meng, Guangxun ^a   Rutz, Mark ^a   Schiemann, Matthias ^a   Metzger, Jochen ^a   Grabiec, Alina ^a   Schwandner, Ralf ^b   Luppa, Peter B ^a   Ebel, Frank ^c   Busch, Dirk H ^a   Bauer, Stefan ^a   Wagner, Hermann ^a   Kirschning, Carsten J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Tularik GmBH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T2.5; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CELL SURFACE RECEPTOR; COMPLEMENTARY DNA; EPITOPE; HYBRID PROTEIN; LIGAND; MEMBRANE PROTEIN; TLR2 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACILLUS SUBTILIS; CELL ACTIVATION; CONTROLLED STUDY; EMBRYO; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIGAND BINDING; MACROPHAGE ACTIVATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SEPSIS; SEPTIC SHOCK; SHOCK; SURFACE PLASMON RESONANCE; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE; DNA, COMPLEMENTARY; EPITOPES; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; MACROPHAGE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85047690873     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20762     Document Type: Article

References (57)

1. Medzhitov, R., and Janeway, C.A. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:295-298.
2. Takeda, K., Kaisho, T., and Akira, S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-376.
3. Raetz, C.R., et al. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5:2652-2660.
4. Ulevitch, R.J., and Tobias, P.S. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:437-457.
5. Lien, E., et al. 2000. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105:497-504.
6. Beutler, B., and Rietschel, E.T. 2003. Timeline. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3:169-176.
7. Wagner, H. 2001. Toll meets bacterial CpG-DNA. Immunity. 14:499-502.
8. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature. 420:885-891.
9. Hotchkiss, R.S., and Karl, I.E. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-150.
10. Martin, G.S., Mannino, D.M., Eaton, S., and Moss, M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554.
11. Roger, T., David, J., Glauser, M.P., and Calandra, T. 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature. 414:920-924.
12. Schimke, J., Mathison, J., Morgiewicz, J., and Ulevitch, R.J. 1998. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. U. S. A. 95:13875-13880.
13. Bochud, P.Y., and Calandra, T. 2003. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ. 326:262-266.
14. Wang, H., et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-251.
15. Jin, H., et al. 1994. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J. Infect. Dis. 170:1323-1326.
16. Yoon, D.Y., and Dinarello, C.A. 1998. Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but nor binding: regulation of IL-1 responses is via type I receptor, not the accessory protein. J. Immunol. 160:3170-3179.
17. Ito, H. 2003. Anti-interleukin-6 therapy for Crohn's disease. Curr. Pharm. Des. 9:295-305.
18. Reimold, A.M. 2003. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am. J. Med. Sci. 325:75-92.
19. Dziarski, R., Jin, Y.P., and Gupta, D. 1996. Differential activation of extracellular signal-regulated kinase (ERK) 1, ERK2, p38, and c-Jun NH2-terminal kinase mitogen-activated protein kinases by bacterial peptidoglycan. J. Infect. Dis. 174:777-785.
20. Kengatharan, K.M., De Kimpe, S., Robson, C., Foster, S.J., and Thiemermann, C. 1998. Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J. Exp. Med. 188:305-315.
21. Schleifer, K.H., and Kandler, O. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36:407-477.
22. Fischer, W. 2000. Phosphocholine of pneumococcal teichoic acids: role in bacteria] physiology and pneumococcal infection. Res. Microbiol. 151:421-427.
23. Fan, X., et al. 1999. Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction. Infect. Immun. 67:2964-2968.
24. Bessler, W.G., Johnson, R.B., Wiesmuller, K., and Jung, G. 1982. B-lymphocyte mitogenicity in vitro of a synthetic lipopeptide fragment derived from bacterial lipoprotein. Hoppe Seylers Z. Physiol. Chem. 363:767-770.
25. Wiedmann, M., Arvik, T.J., Hurley, R.J., and Boor, K.J. 1998. General stress transcription factor sigmaB and its role in acid tolerance and virulence of Listeria monocytogenes. J. Bacteriol. 180:3650-3656.
26. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C.J. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406-17409.
27. Yoshimura, A., et al. 1999. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J. Immunol. 163:1-5.
28. Flo, T.H., et al. 2000. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J. Immunol. 164:2064-2069.
29. Takeuchi, O., Hoshino, K., and Akira, S. 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 165:5392-5396.
30. Edelson, B.T., and Unanue, E.R. 2002. MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J. Immunol. 169:3869-3875.
31. Lembo, A., et al. 2003. Differential contribution of Toll-like receptors 4 and 2 to the cytokine response to Salmonella enterica serovar Typhimurium and Staphylococcus aureus in mice. Infect. Immun. 71:6058-6062.
32. Ozinsky, A., et al. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 97:13766-13771.
33. Takeuchi, O., et al. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13:933-940.
34. Alexopoulou, L., et al. 2002. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8:878-884.
35. Mitsuzawa, H., et al. 2001. Extracellular Toll-like receptor 2 region containing Ser40-Ile64 but not Cys30-Ser39 is critical for the recognition of Staphylococcus aureus peptidoglycan. J. Biol. Chem. 276:41350-41356.
36. Rock, F.L., Hardiman, G., Timans, J.C., Kastelein, R.A., and Bazan, J.F. 1998. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. U. S. A. 95:588-593.
37. Meng, G., et al. 2003. Cellular recognition of tri/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine rich repeat (LRR)/LRR-like motifs of TLR2. J. Biol. Chem. 278:39822-39829.
38. Freudenberg, M.A., and Galanos, C. 1991. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59:2110-2115.
39. Werts, C., et al. 2001. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2:346-352.
40. Wang, J.H., et al. 2003. Cutting edge: bacterial lipoprotein induces endotoxin-independent tolerance to septic shock. J. Immunol. 170:14-18.
41. Picard, C., et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:2076-2079.
42. Medvedev, A.E., et al. 2003. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198:521-531.
43. Weighardt, H., et al. 2002. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169:2823-2827.
44. Gallay, P., Heumann, D., Le Roy, D., Barras, C., and Glauser, M.P. 1994. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc. Natl. Acad. Sci. U. S. A. 91:7922-7926.
45. Lamping, N., et al. 1998. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J. Clin. Invest. 101:2065-2071.
46. Dankesreiter, S., Hoess, A., Schneider-Mergener, J., Wagner, H., and Miethke, T. 2000. Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J. Immunol. 164:4804-4811.
47. Gray, P.W., et al. 1989. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J. Biol. Chem. 264:9505-9509.
48. Jin, H., et al. 1995. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J. Clin. Invest. 95:1947-1952.
49. Levin, M., et al. 2000. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. 356:961-967.
50. Krutzik, S.R., et al. 2003. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat. Med. 9:525-532.
51. Brightbill, H.D., et al. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285:732-736.
52. Wiesmuller, K.H., Jung, G., and Hess, G. 1989. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine. 7:29-33.
53. Heine, H., et al. 1999. Cutting edge: cells that carry a null allele for toll-like receptor 2 are capable of responding to endotoxin. J. Immunol. 162:6971-6975.
54. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., and Strobe, W. 1990. Current protocols in immunology. John Wiley & Sons Inc. New York, New York, USA. 2.5.1-2.7.12.
55. Sing, A., et al. 2002. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. 196:1017-1024.
56. Linder, S., Nelson, D., Weiss, M., and Aepfelbacher, M. 1999. Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc. Natl. Acad. Sci. U. S. A. 96:9648-9653.
57. Schindler, U., and Baichwal, V.R. 1994. Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol. Cell. Biol. 14:5820-5831.